ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $1.57B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-212.00K; Retained Earnings (Accumulated Deficit)USD $-1.42B.
- 2026-03-31: Common Stock, Value, IssuedUSD $16.00K; Additional Paid in CapitalUSD $1.60B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-28.00K; Retained Earnings (Accumulated Deficit)USD $-1.38B.
- 2025-12-31: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in CapitalUSD $1.58B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $253.00K; Retained Earnings (Accumulated Deficit)USD $-1.36B.
- 2025-09-30: Common Stock, Value, IssuedUSD $15.00K; Additional Paid in CapitalUSD $1.55B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $211.00K; Retained Earnings (Accumulated Deficit)USD $-1.35B.
ADAPTIVE BIOTECHNOLOGIES CORPORATION Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $16.00K | $1.57B | $-212.00K | $-1.42B | $142.91M | $150.66M | 3 month · $11.12M 6 month · $23.05M | (m) | (m) | (m) |
| 2026-03-31 | $16.00K | $1.60B | $-28.00K | $-1.38B | $216.34M | $224.24M | 3 month · $11.93M | (m) | (m) | (m) |
| 2025-12-31 | $15.00K | $1.58B | $253.00K | $-1.36B | $218.79M | $225.00M | 12 month · $51.48M | (m) | (m) | (m) |
| 2025-09-30 | $15.00K | $1.55B | $211.00K | $-1.35B | $204.44M | $204.25M | 3 month · $13.26M 9 month · $38.76M | (m) | (m) | (m) |
| 2025-06-30 | $15.00K | $1.54B | $73.00K | $-1.36B | $179.72M | $179.54M | 3 month · $13.36M 6 month · $25.51M | (m) | (m) | (m) |
| 2025-03-31 | $15.00K | $1.52B | $134.00K | $-1.33B | $190.42M | $190.22M | 3 month · $12.15M | (m) | (m) | (m) |
| 2024-12-31 | $14.00K | $1.51B | $166.00K | $-1.30B | $202.71M | $202.49M | 12 month · $53.61M | (m) | (m) | (m) |
| 2024-09-30 | $14.00K | $1.49B | $497.00K | $-1.27B | $223.77M | $223.57M | 3 month · $13.52M 9 month · $40.78M | (m) | (m) | (m) |
| 2024-06-30 | $14.00K | $1.48B | $-182.00K | $-1.24B | $241.60M | $241.43M | 3 month · $12.96M 6 month · $27.26M | (m) | (m) | (m) |
| 2024-03-31 | $14.00K | $1.47B | $-106.00K | $-1.19B | $274.91M | $274.77M | 3 month · $14.30M | (m) | (m) | (m) |
| 2023-12-31 | $14.00K | $1.45B | $215.00K | $-1.14B | $308.40M | $308.28M | 12 month · $62.91M | (m) | (m) | (m) |
| 2023-09-30 | $14.00K | $1.44B | $-250.00K | $-1.07B | $361.73M | $361.64M | 3 month · $15.34M 9 month · $47.35M | (m) | (m) | (m) |
| 2023-06-30 | $14.00K | $1.42B | $-893.00K | $-1.02B | $396.04M | $395.97M | 3 month · $17.34M 6 month · $32.02M | (m) | (m) | (m) |
| 2023-03-31 | $14.00K | $1.40B | $-1.91M | $-976.78M | $424.02M | $423.95M | 3 month · $14.67M | (m) | (m) | (m) |
| 2022-12-31 | $14.00K | $1.39B | $-4.12M | $-919.08M | $464.17M | $464.10M | 12 month · $55.48M | (m) | (m) | (m) |
| 2022-09-30 | $14.00K | $1.37B | $-5.97M | $-878.95M | $487.84M | $487.81M | 3 month · $14.14M 9 month · $41.18M | (m) | (m) | (m) |
| 2022-06-30 | $14.00K | $1.36B | $-5.80M | $-833.67M | $518.30M | $518.32M | 3 month · $14.18M 6 month · $27.04M | (m) | (m) | (m) |
| 2022-03-31 | $14.00K | $1.34B | $-4.78M | $-781.63M | $553.21M | $553.25M | 3 month · $12.86M | (m) | (m) | (m) |
| 2021-12-31 | $14.00K | $1.32B | $-1.14M | $-718.89M | $603.99M | $604.10M | 12 month · $43.25M | (m) | (m) | (m) |
| 2021-09-30 | $14.00K | $1.31B | $7.00K | $-657.46M | $651.51M | $651.54M | 3 month · $11.64M 9 month · $31.38M | (m) | (m) | (m) |
| 2021-06-30 | $14.00K | $1.29B | $216.00K | $-601.55M | $693.18M | $693.31M | 3 month · $11.25M 6 month · $19.73M | (m) | (m) | (m) |
| 2021-03-31 | $14.00K | $1.28B | $631.00K | $-552.25M | $725.59M | $725.72M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $14.00K | $1.25B | $893.00K | $-511.61M | $743.27M | $743.27M | 12 month · $24.76M | (m) | (m) | (m) |
| 2020-09-30 | $13.00K | $1.24B | $1.43M | $-467.04M | $775.05M | $775.05M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $12.00K | $958.10M | $2.15M | $-430.32M | $529.94M | $529.94M | (m) | (m) | (m) | (m) |
| 2020-03-31 | $12.00K | $945.03M | $3.31M | $-396.79M | $551.56M | $551.56M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $12.00K | $935.83M | $671.00K | $-365.48M | $571.04M | $571.04M | (m) | (m) | (m) | (m) |
| 2019-09-30 | $12.00K | $930.21M | $572.00K | $-344.87M | $585.92M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $1.00K | (m) | $382.00K | $-330.92M | $-284.37M | (m) | (m) | $46.16M | 3 month · $3.33M 6 month · $6.38M | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | $-273.47M | (m) | (m) | (m) | 3 month · $3.05M | (m) |
| 2018-12-31 | $1.00K | $37.90M | $-107.00K | $-295.91M | $-258.11M | $-258.11M | (m) | $37.90M | 12 month · $11.15M | 12 month · $-3.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | $-248.08M | (m) | (m) | (m) | 3 month · $2.55M 9 month · $8.10M | 9 month · $-3.00K |
| 2018-06-30 | (m) | (m) | (m) | (m) | $-242.44M | (m) | (m) | (m) | 3 month · $2.45M 6 month · $5.55M | 3 month · $-1.00K 6 month · $-3.00K |
| 2018-03-31 | (m) | (m) | (m) | (m) | $-233.61M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $-224.62M | (m) | (m) | (m) | 12 month · $6.92M | 12 month · $-89.00K |
| 2016-12-31 | (m) | (m) | (m) | (m) | $-189.73M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |